Anti-EpCAM Aptamer Synthesis and Modification Service

EpCAM has been shown to be a marker of cancer stem cells (CSCs) or tumor-initiating cells (TICs), and its expression in cancer is associated with poor prognosis. The use of anti-EpCAM aptamers for targeted drug delivery is promising in cancer therapy and has attracted considerable interest from the scientific community.

CD Bioparticles offers services for the synthesis and modification of anti-EpCAM aptamers. We synthesize custom aptamers with high affinity for the receptors of your target. We provide fundamental research into the role of aptamers in targeted cancer drug delivery through aptamer synthesis. The aptamers we synthesize play a crucial role in the targeted diagnosis and treatment of cancer.

Anti-EpCAM Aptamer Service Background

Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that is considered a candidate ligand for active targeting. Studies have shown that EpCAM is normally expressed at low levels in healthy epithelial cells and at higher levels (up to 1000-fold) in cancer cells. During cancer development, the expression pattern of EpCAM shifts from the basement and basolateral membranes of normal epithelial cells to the apical surface of tumor epithelial cells. This differential expression makes EpCAM a promising drug delivery ligand that could improve the therapeutic index of drugs.

Current research on aptamers is attracting considerable attention from scientists. Selective targeting of NDDS by anti-EpCAM-specific aptamers may be an effective way to deliver chemotherapeutic agents to the tumor microenvironment.

Fig. 1 EpCAM-aptamer schematic. (Song Y, et al., 2013)

Our Anti-EpCAM Aptamer Services

CD Bioparticles is engaged in the synthesis and modification of anti-EpCAM aptamers. The aim of our service is to synthesize and modify an aptamer against EpCAM. This will enable us to support research into targeted drug delivery to tumor cells in vitro by coupling the aptamer to other substances to enhance cellular uptake. Our services include but are not limited to the following:

• Anti-EpCAM Aptamer Design

We will work with you to design aptamers specifically for the EpCAM receptor or any other target protein of interest.

• Anti-EpCAM Aptamer Synthesis

We offer bespoke anti-EpCAM aptamer synthesis services using a range of techniques including solid phase, enzymatic and chemical synthesis.

• Anti-EpCAM Aptamer Modification

We can further modify anti-EpCAM aptamer to improve their binding affinity, stability, and specificity to target proteins by chemical modification, conjugation with different tags or fluorophores, and the addition of anti-nuclease ligands.

• Characterisation of Anti-EpCAM Aptamers

A range of assays can be used to characterize the binding properties of anti-EpCAM aptamer, including surface plasmon resonance (SPR), fluorescence polarisation (FP), and gel shift assays.

• Anti-EpCAM Aptamers Targeted Drug Delivery

We can demonstrate that the anti-EpCAM aptamers we develop can direct tissue-specific drug uptake through in vitro and in vivo assays.

• Anti-EpCAM Aptamer Optimisation

We offer optimization services to improve the properties of aptamers for your specific application. This includes optimization of the aptamer sequence, modification of the aptamer structure, and optimization of the attachment chemistry.

Deliverable Results

• Aptamer characterisation results
• Aptamer specificity and affinity analysis report

Contact Us

CD Bioparticles offers services for the synthesis and modification of anti-EpCAM aptamers. Our team has developed a variety of specific aptamers that allow selective, targeted delivery of drugs to the tumor microenvironment. If you are interested in our services, please do not hesitate to contact us.

Quotations and Ordering

References

1. Mashreghi, M.; et al. Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma. Nanoscale Res Lett. 2020; 15 (1): 101.
2. Song, Y.; et al. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem. 2013; 85 (8): 4141-9.